2022-03-31-accounts

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

ANNUAL KEPOKT AND ACCOUNTS 12021-2022 l*t IJM•u THI TUM•UI THE BRAIN TUM•UR CHARITY

Report of the Trustees 3 a. Strategic Report �� b. Statement of the Trustees’ responsibilities 38 Independent auditor’s report 39 �� 43 �� 44

CHAIR’S REPORT

�� stood down from the Board and stepped �� support as Interim CEO and Interim Deputy ��

First of all, may I start with a heartfelt thank you for standing ��

This year has been one requiring resilience from us all - a year where the needs of �� only been heightened. NHS and community resources are at full stretch, people are ��

We were saddened to hear of the death of The Charity’s President Professor Sir �� UK, one of the charities that merged to form The Brain Tumour Charity, and continued his work with The Charity after �� particularly impactful in the early days of �� of the app and access to data. Our thoughts are with his family and those who knew him.

Our response has been to turn to The ��

By joining together as a stronger, �� meaningful change, despite the challenging �� in this Report - our inspiring new cohort of Young Ambassadors, our relentless founding Trustees and our indefatigable Head of Strategy – but standing with them are countless others similarly passionate about ��

�� for standing alongside us through these �� a donor, a change maker or helping us defeat brain tumours in the lab or clinic.

Our goals remain ambitious – to double �� growing union with you, our community, takes us closer towards these goals and �� we’re using this as a springboard to a better future by creating our next strategy together - Beyond Brain Tumours . It’s not too late to join in and I look forward to ��

�� also begin funding new research projects ��

In the meantime, on behalf of all those �� challenges past, present and future.

This progress has not been easy. On behalf of my fellow Trustees, I would like to thank The Charity’s leadership team - with particular thanks to our Interim CEO and �� to his research role and we resume the search for a permanent CEO, I’m delighted and most grateful that two of our longstanding and highly experienced Trustees,

��

Jack Morris CBE

Chair of Trustees

The Brain Tumour Charity Annual Report and Accounts 2021-2022

YOUNG AMBASSADORS

In 2021, we were delighted to �� Young Ambassadors to The Charity.

Our Young Ambassadors are an integral part of The Brain Tumour Charity, working tirelessly to raise awareness and create a �� brain tumour.

By sharing their deeply personal experiences of a brain tumour, they help us to better connect with those who come to us for support, especially other young adults, and help us encourage new ��

�� contributed their time and expertise by �� organisational strategy – Beyond Brain Tumours.

�� their enthusiasm and deep commitment. �� reacted to the harshest life experiences ��

Losing my Mum to a brain tumour, at such a young age, has been the hardest thing �� going through something similar. I want to not only help raise awareness of brain tumours, but also help to raise awareness �� I felt that I lost my Mum long before she passed, as her tumour changed her in many ways. I wish I had opened up more �� to be a support to others going through this struggle.

Amy

�� battle with a grade 4 Glioblastoma last �� debilitating this illness was for Dad, but in many ways, it was just as debilitating for my Mum, sisters and me too. Whilst it would be far too easy for me to dwell in bitterness, frustration and disappointment, I know that my Dad would not want this for me. Being a Young Ambassador means that I’m able to direct my energy into ��

Kajal

I wanted to become a Young Ambassador because I would like to become more �� Charity as it has helped me so much. I would also like to campaign for better and faster treatment for people with low grade tumours like mine.

Being diagnosed with a brain tumour can �� the support The Brain Tumour Charity �� a Young Ambassador.

Jazz

I became a Young Ambassador to be there �� been impacted by a brain tumour, as well as to help raise awareness for brain tumours (especially in the UK) because I know it is a problem, through personal �� potential to make an impact and I would �� media about how to tackle brain tumour awareness and diagnosis.

Rhudi

I’m excited to become a Young Ambassador to support other young �� compared to when I had my treatment ten years ago, is phenomenal, and I’m really looking forward to engaging with other young people going through similar �� brain tumours.

Rebecca

Kate

Meet our Young Ambassadors

4 ��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

�� and incidence from cancer registry data for England, Northern Ireland, Wales and Scotland.

�� research spend (from our Annual reports). NCRI data: Cancer Research Spend Data �� from: http://www.ncri.org. uk/what-we-do/researchdatabase/

3 Cancer Research UK, https:// www.cancerresearchuk. org/health-professional/ cancer-statistics/statisticsby-cancer-type/brainother-cns-and-intracranialtumours/incidence, ��

CEO’S REPORT

��

�� thanks for your unwavering support during another ��

�� much to the relief of the community and ��

We’re all here for one simple reason – �� [�] �� a brain tumour diagnosis each year and, despite momentum gathering from the threefold increase in research funding ��[�] �� [3]

Perhaps most exciting of all, we launched our forward-thinking new research strategy, Accelerating a Cure. It’s impossible not to read this and be ��

�� look forward to! As I write, we’re launching our long-awaited Better Safe Than Tumour campaign to raise awareness of common brain tumour signs and symptoms, building on the success of our Headsmart ��

It’s important to remember that these aren’t just numbers. The recent death �� his diagnosis of a glioblastoma, shone a harsh light on the brutal reality behind these statistics. We know Tom’s death hit the community hard as his story is �� left to go.

We’re also deep into the process of engaging our UK and wider community in co-creating our next organisational strategy, Beyond Brain Tumours . This �� people from across the brain tumour community and there’s still time for you ��

��

�� and reaching the incredible milestone ��

It’s been a busy year for The Charity, regrouping after the pandemic and rebuilding our foundations stronger than ��

�� users, including making it easier for researchers to use BRIAN’s data to accelerate a cure

��

�� centres in the UK, helping to hold treatment centres accountable for gaps in care

Graham Norton

Interim CEO

OUR GOALS AND VALUES

OUR GOALS

�� tumours are defeated and our goals are our blueprint for getting there. Simply put, �� these goals, we know that it’s not the right direction for us.

�� unashamedly ambitious as this is the only way we’ll see a real and last ��

��

�� brain �� of life in the UK

�� 82� ��

OUR VALUES

��

The way we work is always:

PIONEERING

We're relentless and courageous in the ��

PASSIONATE

�� a brain tumour has the highest quality of ��

COLLABORATIVE

�� networks, partnerships and a strong ��

SMART

We’re focused and intelligent in our approach to defeating brain tumours.

�� more than, 50%+

was spent on research

��

CLARE NORMAND, OUR HEAD OF STRATEGY, HONOURED WITH OBE

Clare has been at the heart of The Charity since she ��

----- Start of picture text -----
��
----- End of picture text -----

Clare’s amazing work was recognised in the �� tumour charities. She’s been at the heart �� leading on our strategy and making sure �� and impact.

Clare began supporting The Samantha Dickson Brain Tumour Trust (now The Brain �� year-old son, Alec, was diagnosed with an inoperable brain tumour.

Alec tragically passed away just ten months after his diagnosis.

Since then, Clare, her husband Christopher, ��

�� ambitious Defeating Brain Tumours �� £38m towards research into brain tumours ��

Always mindful that our greatest resource is the passionate brain tumour community, Clare masterminded our transitional Leaning In strategy that allowed The �� drawing on our strengths and leaning into the community to maximise the impact we ��

Now, Clare is making sure our next strategy, Beyond Brain Tumours , is truly led by the needs of the community through a process �� their insight, time and work to the new �� brain tumour researchers, healthcare professionals and other charities that are committed to defeating brain tumours.

�� has played a key part in the growth in income �� the years.

Clare said, "Singling me out for an OBE must be put in context: my whole family has �� the promise he asked of us to stop this happening to others; there are countless �� hundreds of other people working tirelessly ��

“In accepting this honour, I consider myself �� and I hope this public recognition of our �� further support.”

In response to the news, our CEO said: �� our strategy, shaping us into the worldleading charity that we are today.

�� in the growth in income and impact of The �� continues to be a beacon of support and inspiration to so many in our community ��

�� years and I see her as the beating heart of �� and personality.”

David Jenkinson

�� past Interim CEO ��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

OUR OBJECTIVES AND ACTIVITIES

��

DEFEATING BRAIN TUMOURS: LEANING IN

�� health by supporting research and publishing useful results of research into the nature, causes, diagnosis and treatment, as well as the social consequences of, tumours of the brain ��

�� brain tumours, on brain tumour care, on the pace of research and on our own resources.

In order to support the community’s heightened needs through the pandemic �� by leaning into our strengths, becoming a ��

��
�� system, their families and carers, through ��
�� all areas relating to tumours of the brain ��

To do this, as well as make sure we’re in the best possible position to accelerate a cure in a much-changed post-pandemic world, this strategy was built around four pillars of work:

PUBLIC BENEFIT STATEMENT

�� Commission’s general guidance on public �� Charity are carried out wholly in pursuit of ��

Power of Data

We’ll harness the power of data to accelerate research, tackle inequality, inform change, empower our community and maximise our impact.

Best Care Everywhere

�� the UK, empowering the community to �� where they’re located and helping treatment centres reach the highest possible standards.

Voices for Change

�� fundraisers or change makers.

Make it Count

We’ll use our resources, skills and technology �� maximise our impact with minimal resources.

THE GIFT OF TIME

�� based on the powerful and �� our partner Runningman Two for our Winter Appeal.

Watch the

��

Being someone who is part of a family that has been directly �� at Christmas time; this campaign ��

�� time together.

�� Buckley family - I wanted to raise as much money as possible for this amazing cause.

Tom Buckley, a producer at Runningman Two, drew on his own experiences of a �� tumour to bring the idea to life in a way that deeply resonated with the community.

Tom Buckley

Producer at Runningman Two

The Winter Appeal was a huge success and as well as increasing the reach of the brand ��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

��

HIGHLIGHTS TAKING BRIAN TO OF 2021/22 THE NEXT LEVEL

7,200 registered BRIAN users

Our BRIAN (the Brain tumouR Information and Analysis Network) project continues to go from strength to strength. We smashed ��

The Clinical Trial Link allows researchers to collect data from consenting clinical trial participants through BRIAN. This makes it easier for researchers to securely collect data, which is ring-fenced from the general data analysis in BRIAN until the trial has �� been reported.

�� our BRIAN app will always be led by those who use it, so we regularly meet with BRIAN users and Young Ambassadors to get their thoughts – as well as running feedback ��

�� of data from both NHS Digital and Public Health England. In combination with our access to data from Scotland, Wales and Northern Ireland, this has allowed us to �� as it now empowers the community in the �� treatment and care in relation to others in their home country.

�� tested and released two new features, the Seizure Tracker and Clinical Trial Link, that help better support the community and make it easier for researchers to collect the data they need for studies.

The Seizure Tracker allows users to record the type, time and duration of their seizures, which can then be shared with their clinicians.

should reduce delays in granting access to researchers. After a rigorous selection process, we’re now working to integrate our chosen TRE with BRIAN and transfer the data to it.

IMPROVING SAFE AND SECURE ACCESS TO DATA

Making it easier for researchers to safely and securely access the data collected by BRIAN is key to our strategy for defeating brain tumours.

Ensuring the security of both the app and the data stored within BRIAN is a top priority for The Charity and in the past year the app ��

To help speed up the process of data access and make it easier for researchers �� working with Health Data Research UK (HDRUK) to register BRIAN on their �� we compiled the metadata in BRIAN to allow researchers to quickly understand �� to the HDRUK platform, which will allow us to link into the national data usage register it curates and help ensure transparency around how the data is used.

�� BRIAN is now in the top six apps in ORCHA’s

app library and is its top-rated cancer app.

�� ORCHA rating for BRIAN

�� explored the use of a Trusted Research �� of the data they need to conduct their analyses without sharing the entire BRIAN �� enhance the security of the data and

NHS Digital also performed its annual audit of our processes and data security. BRIAN was once again rated in the top category as being a low risk to the security of the NHS data or improper usage.

----- Start of picture text -----
��
----- End of picture text -----

The Brain Tumour Charity Annual Report and Accounts 2021-2022

FUNDING NEW LAUNCHING OUR RESEARCH NEW RESEARCH STRATEGY

�� hit The Charity hard and we had to make �� research to make sure we were able to protect the projects we’d already pledged to support.

�� to traditional grant funding, we published our new research strategy - Accelerating a Cure.

�� of Accelerating a Cure was led by the community. We consulted with people ��

This year, once it became clear that income �� to return to new grant funding for research.

We progressed three grant calls during the �� opening for the third cohort of applicants. We look forward to selecting the successful ��

While groundwork for the strategy had mostly been completed pre-pandemic, we �� crisis and use that knowledge to ensure Accelerating a Cure would be successful in the much-changed post-pandemic research landscape.

We also began undertaking a review of our funding to the Everest Centre for Paediatric Low Grade Glioma as it nears �� from the centre was integral to the new �� by the World Health Organisation in December 2021.

Accelerating a Cure builds on the incredible �� research strategy, A Cure Can’t Wait, while identifying areas that need extra work to �� Key to this will be kick-starting translational research to ensure our world-class discovery research is used to develop new treatments for those living with a brain tumour.

�� methylation, small marks on the DNA of cells telling them which genes to use and �� and made major contributions to the new �� funded researchers.

�� role in our new approach to research that aims to enhance quality of life. We plan on �� practice around the neuroscience centres �� those practices are adopted widely.

You can read more about Accelerating a Cure here.

Thank you, on behalf of all of us touched by this brutal disease. We’re �� and direction of Accelerating a Cure �� future for those with brain tumours. �� further, faster!

The Involvement Network

CELEBRATING OUR FOUNDERS

�� our Founders, Neil and Angela ��

Neil and Angela founded The Trust, �� as The Brain Tumour Charity, in memory of their daughter Samantha, who passed away from a rare form of glioma when she was just 16.

�� done for the charity, our sincere and heartfelt �� to change the way people are being treated, being supported and an impact to change �� tumour diagnosis."

Dr David Jenkinson

��

�� of this is the fact that so little was being done for this disease. Brain tumours reduce �� the highest burden of any cancer or major disease.

�� brain cancer, amongst the highest increase ��

Angela Dickson MBE ��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

The Brain Tumour Charity Annual Report and Accounts 2021-2022��

HIGHLIGHTS CONTINUING TO MEET THE OF 2021/22 GROWING DEMAND FOR OUR SUPPORT SERVICES

�� website for help this year.

----- Start of picture text -----
1.3M
��
our website for help
----- End of picture text -----

Our Online Brain Tumour Support Groups �� empowering people to support each other. They also help create a much-needed sense �� by a brain tumour with others who share their experiences at a time when they can often feel most isolated and alone.

�� people supported one-to-one

It’s only thanks to the incredible support we �� call to our Support and Information Line, �� Brain Tumour Support Groups and work �� resources for the community.

24,000 �� Brain Tumour Support Groups

AMPLIFYING THE COMMUNITY’S VOICE TO MAKE MEANINGFUL CHANGES IN CARE

��

Thanks to the community sharing where they �� were gaps, we were able to send patient �� neuroscience centres in the UK to help those ��

----- Start of picture text -----
25/30
----- End of picture text -----

�� reports on their standard of care

�� the assessment of neuroscience centres �� neuroscience centres in the UK are now recognised as Centres of Excellence.

�� care, with many centres adding Clinical Nurse Specialist and Allied Health �� to make successful business cases for other �� community says is a shortfall.

----- Start of picture text -----
�
17/30
----- End of picture text -----

neuroscience centres recognised as Centres of Excellence

�� this patient and clinical-led assessment �� making change.

�� people’s experiences depending on where �� as well as gaps in care across the UK.

This is unacceptable and we’re working to close those gaps by sharing best �� of Excellence, as well as with the �� continue to persist.

�� eight policy consultations across the UK, ensuring that better access to a CNS or key worker was recognised by the National Institute for Health and Care Excellence �� its new Quality Standard on brain tumours in England.

�� Parliament to the All-Party Parliamentary Group on Brain Tumours. This ensured the �� in the Health and Social Care Select Committee’s Report on progress towards ��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

SUPPORTING HEALTHCARE PROFESSIONALS

As well as highlighting the gaps in care, we’re also helping to close them with practical solutions.

�� professionals to spot the signs and symptoms of a brain tumour more �� Better Safe than Tumour �� healthcare engagement work to support this aim of reducing diagnosis times for adults and children.

6,141 optical professionals trained

Our BRIAN app is helping healthcare �� to patients and is now embedded in the pathway of four neuroscience centres. �� an unplanned admission because they contacted a patient when they saw their well-being scores dropping.

We were also made aware of a case where �� his seizures following treatment for a glioblastoma, after being introduced to the app by his Clinical Nurse Specialist. It �� was identifying “brain fog” lasting for a few minutes and after showing his neurologist, his anti-epileptic medication was increased and no further episodes were recorded.

A new BRIAN feature aimed towards closing �� year, after consultation with our community of healthcare professionals. The My Support Plan feature is a Holistic Needs Assessment (HNA) and support planning tool, which �� exists across the UK.

AN AWARD-WINNING PARTNERSHIP

�� absolutely awesome; they kept us focused �� Marketing Cloud.

�� Marketing Partnership of the Year �� Charity Awards for an innovative �� hours of time donated by the team ��

“We wanted to build a test-and-learn culture ��

“We wanted to create and launch a new campaign and with their help, guidance and encouragement, we did.

�� supporter experience, transforming how we understand and talk to our supporters. The �� workshops and training sessions - ultimately �� model and pilot campaign - featuring �� around Britain!

�� workshops, focused team training and ��

�� short space of time – we cannot thank them enough!”

The campaign was a great success, but �� partnership will be many times greater as we use the new approach to better communicate with all our supporters – �� into the community and deepening their long term relationship with The Charity.

Gina Almond

��

HIGHLIGHTS ACHIEVING RECORDOF 2021/22 BREAKING INCOME

�� generous and dedicated community we �� especially like to shout out our major donors, who contributed a remarkable ��

£11.5M ��

�� amazing supporters helped us bounce back ��

��

up their running shoes and took to the streets to support The Charity, raising an astonishing ��

We also celebrated two major milestones �� in our success.

�� sure our team stays connected to each other and the community. This year, the technical �� tremendous support for our matched-funding ��

�� important their support has been. By making �� and increase the scale of our work. This was especially important during the pandemic, allowing us to seamlessly transition to working from home and continue to support the community.

�� Moody has gone to some extreme lengths to tackle brain tumours – including cycling through rainforests and trekking to both the �� defeat brain tumours!

Lewis and his wife, Annie, were inspired to �� after a battle with a rare form of cancer and �� his memory.

LIVING UP TO OUR VALUES AS PIONEERS

With the help and support of the community, we were also able to try some exciting new things this year.

�� animation that was gifted to us by our partner Runningman Two. It appeared across a wide ��

We’re so proud of what Lewis, Annie and �� facilitated by The Charity.

FORGING AN AWARDWINNING PARTNERSHIP

�� dip our toes into the exciting waters of ��

�� gifted time, The Charity worked with �� to create an audience segmentation model and automated journeys for our �� possible experience.

After consultation with our Supporter Groups and family-led charities, we also launched our CREATE design platform that empowers the community to produce their own fundraising and awareness materials using our design assets.

�� Daubeny, and resulted in an increase in donations, an increase in engagement with our content and a doubling in the ��

Throughout 2021/22 we also developed two new campaigns that will launch in the summer of 2022, our Win Big Weekly Lottery and our long-awaited signs and symptoms campaign – Better Safe Than Tumour.

�� campaigns to audience led-campaigns. This amazing project also resulted in an award for Marketing Partnership of the Year at the Third Sector Business Charity Awards.

Better Safe than Tumour will build on our successful Headsmart campaign and expand �� too. We look forward to the community seeing this new campaign and helping us spread it far and wide across all channels.

----- Start of picture text -----
��
----- End of picture text -----

The Brain Tumour Charity Annual Report and Accounts 2021-2022

CELEBRATING OUR CELEBRITY SUPPORTERS

We owe our celebrity supporters a great deal of thanks for helping us raise funds and spread awareness of the cause.

We’d especially like to express our gratitude to Peter Kay for coming out of retirement to �� Ambassador, Laura Nuttall. We’d also like to thank Tom Daley for his continued support and TikTok knitting antics.

We’d also like to thank Nicki Chapman for her continued support and championing of our work in the media, and for being a ��

We, along with the entire community, were deeply saddened by the passing of Tom ��

REACHING AND MOBILISING MORE VOICES FOR CHANGE

�� public awareness of the research we fund, �� campaigning for change and the ways we’re raising money to help defeat brain tumours sooner.

�� people take action this year to become �� parliamentarians and celebrity supporters. Thanks to the amazing support take action ��

�� Ambassadors, we were also able to host �� since the pandemic began. We shared �� publically get their support.

A huge thank you to Tom, his wife Kelsey and his band members in The Wanted, ��

�� and the song’s writers and producers for generously donating all net proceeds for the �� (for Tom)’.

�� indefatigable Clare Normand was honoured with an OBE this year for her work on behalf �� Tumour Charity.

MAKING SURE THE COMMUNITY’S VOICE IS PRESENT IN EVERYTHING WE DO

�� group we’re able to ensure the community’s �� products and campaigns.

�� organisational strategy, Beyond Brain Tumours , as a community.

��

�� working group being guided by a steering �� by a brain tumour, researchers, healthcare professionals and other brain tumour charities, including international charities.

�� approach called ‘Co-Creation’, is a new and highly ambitious way to designing the path forward for The Charity.

It will be both challenging and, hopefully, extremely rewarding and successful. The �� process creating a strategy which the whole brain tumour community has contributed ��

Neil Munn

�� of Beyond Brain Tumours

BRINGING OUR TEAM BACK TOGETHER

�� of attending.

In September 2021 we were able to ��

The aim of the day was to focus on the challenges facing the community, get the �� of our new strategy and get us all thinking �� future change.

It was so good to come together as a team, cement why we do what we do and celebrate ��

�� mix of speakers from the community, �� carers and healthcare professionals.

----- Start of picture text -----
��
----- End of picture text -----

��

HIGHLIGHTS ADAPTING TO A NEW NORMAL OF 2021/22

Keeping our team connected to each other and the community during the pandemic was vital as we refused to slow down and compromise our mission of moving further, faster towards a world where brain tumours are defeated.

We take a huge amount of pride in our culture and connection with those we support, so it’s fair to say there was a steep learning ��

�� to settle into a new normal that embraced the hybrid nature of the post-pandemic workplace.

�� collaborate in person again, but our time �� work together remotely – setting us up for a bright future of teaming with international partners and making alliances with external organisations.

�� means our team enjoys the best of both worlds and has allowed us to attract a wider ��

�� a great opportunity to spend time together �� our progress to date. We dedicated a lot of time to hear from the community, learning �� brain tumours and understanding what’s important to them.

It was a stark reminder of why we must continue to push for kinder treatments and, ultimately, a cure.

COMMERCIALISING BRIAN

�� know-how that brings our BRIAN project to life, it became apparent this model would be �� illnesses.

�� has embarked in commercialising the technology underlying BRIAN (it’s important to note that this does not include the data held within BRIAN) and has created new commercial trading subsidiary companies to do this. It’s anticipated this new commercial �� a new income stream for The Charity within the next two years.

�� their time, experience and expertise so �� our goals.

CELEBRATING OUR VOLUNTEERS

One of the things we’re proudest of is ��

�� fourth cohort of Young Ambassadors to The �� 1,000+ Our Young Ambassadors embody our ethos �� of being a community-led charity. They’re experience and expertise hopeful and determined and, like all our �� forward and represent The Charity across �� from fundraising and spreading awareness support and research.

�� from fundraising and spreading awareness of the signs and symptoms of a brain tumour in their local communities, to �� our London Marathon runners and quality checking the accuracy of our medical and ��

��

----- Start of picture text -----
The Brain Tumour Charity Annual Report and Accounts 2021-2022
----- End of picture text -----

The Brain Tumour Charity Annual Report and Accounts 2021-2022

EMBRACING A NEW WAY OF FUNDING RESEARCH

�� to be able to guarantee we could continue �� existing research projects, we were forced to pause our plans to fund new research through traditional grants funding.

This meant we needed to embrace a new way of funding if we were going to support pioneering new projects.

�� for people with recurrent glioblastoma (GBM).

£450,000 raised in our cannabinoids appeal

Supported by generous major donors �� platform, and boosted by major national and �� members of our community), we were able �� one week!

We were then able to raise the additional funds required thanks to the support of the public and global research community, �� from Leeds Hospitals Charity.

Thanks to this new way of raising funds for ��

�� accelerate these answers and are so grateful �� this study possible – thank you.

“We’d also particularly like to thank Leeds �� patients to access the trial at Leeds Teaching Hospitals.

�� promising and we now look forward to �� a major step forward in our ability to treat this ��

�� ��

LEANING IN TO OUR RESPONSIBILITY FOR EQUALITY, DIVERSITY AND INCLUSION

�� in creating a fairer society and acknowledge ��

�� plan that demonstrates our commitment to equality, inclusion and rooting out discrimination in all its forms.

To support this we established an Equality, �� comprised of team members from across The Charity and with two team members acting as �� also established a new Trustee Committee for ��

EXCEPTIONAL RE-APPOINTMENT OF TRUSTEES

The pandemic has created a unique set of �� throughout the world and The Charity is no exception. It also coincided with the departure of the CEO after ten years of �� After careful consideration by The Charity’s Board, following a rigorous appraisal and in accordance with The Charity’s constitution, in �� the term by one year of two trustees, Berrie Norton and Graham Lindsay. Graham Lindsay �� the Interim CEO and leadership team.

Berrie Norton has had a long term

�� Committee and a role in the recruitment of a new CEO. Graham Lindsay sat on the ��

“We are delighted to announce that, thanks to the support and generosity of so many in the community, the ARISTOCRAT trial will begin ��

�� interest among patients and researchers alike for some time about the potential �� glioblastomas. We’re really excited that

The Brain Tumour Charity Annual Report and Accounts 2021-2022

��

FINANCE REVIEW

��

The speed of growth combined with the remarkable generosity of the ��

�� and scale back up operations following the pandemic.

Income from Major Gifts and Appeals were also substantially up, with the most notable �� cannabinoids as a treatment for people with recurrent glioblastoma (GBM).

INCOME

�� portfolio of income streams, with no reliance �� security in funding multi-year research commitments. In the year income was up year-on-year in most areas but there were a few notable items.

The Charity also applied for and was �� fund from the Medical Research Council. �� assist charities funding medical research ��

The ending of social distancing and restrictions on mass gatherings has �� once more. Accordingly, income from �� corporate fundraisers more than doubled ��

�� of the increase is the cost of physical �� year in response to the pandemic.

EXPENDITURE

��

�� due to research projects running behind schedule during the pandemic which has required rebudgeting of the timing of grants.

��

The Charity has a trading subsidiary, TBTC Trading Limited. The subsidiary, which is wholly owned by The Charity, carried out �� which is to be donated to The Charity.

Patient support and campaigning and awareness expenditure also declined year-on-year. This was primarily due to lower salary costs after the size of the �� pandemic and the time it takes to recruit ��

The Charity also formed two new subsidiaries, Acquist Data Holdings Limited �� which were dormant.

�� assets. Current forecasts do not expect ��

INVESTMENTS AND CASH

�� markets and this was compounded by the ��

��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

RESERVES POLICY

��

�� of at least six months’ operational costs to ensure the long-term sustainability of our �� our research commitments. The annual ��

��

�� committed research expenditure totalling £8.3m which was subject to satisfying of our ongoing monitoring requirements and ��

Our Supporter Groups typically express a �� should be spent. These preferences usually �� and The Charity has earmarked these funds �� Supporter Groups is designated by the �� each group.

�� to be utilised to commission further research ��

�� and reports to the main Board of Trustees.

INVESTMENT POLICY

�� to time.

�� managers is to hold a mixture of good �� of generating a balance between capital �� the Trustees consider the cash position of The Charity and our projected short and �� manager performance is measured against established market benchmarks suitable for ��

�� far as practical. At the year end, The Charity ��

�� Ukraine, the portfolio generated income of �� in commercialising the intellectual property �� BRIAN, The Charity’s database tool. The Charity has formed new subsidiaries for ��

EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is �� pay and reward structures for all �� is also responsible for setting senior �� taken account of skills and experience,

��

The long-term success and performance of The Charity is directly linked to the �� of our employees. We recognise the �� and focus on building organisational �� across The Charity is encouraged.

The work we do wouldn’t be possible without the incredible contribution we �� across the UK who support a wide range �� information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and ��

RISK FACTORS

�� risks to which The Charity is exposed. �� established systems and procedures to manage them such that they are part of the senior leadership’s regular management �� makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how ��

�� strategy, intended to widen the balance of �� to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain at �� year is known income at the start of the �� optimise stewardship plans.

��

enough high-quality research projects. �� the brain tumour research community and working to build capacity in the sector. We �� emphasis on building relationships with key researchers.

�� in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage �� monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be �� stakeholders and other key groups.

That our IT infrastructure is not adequate �� managed externally by an IT solutions company.

�� We outsource our IT hosting to a third �� for datacentres and ensure that we �� and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random �� websites use SSL technology. In addition, ��

��

�� incident management plan and this was �� in the community to deal with the anxiety and practicalities caused by the pandemic. �� impact on The Charity.

The Brain Tumour Charity Annual Report and Accounts 2021-2022

GOING CONCERN

�� which are updated on an annual basis, as ��

�� but as the restrictions associated with �� The Charity has adapted and returned ��

OBJECTIVES FOR 2022-23

�� the year are:

�� Best Care Everywhere �� of treatment centres in the UK and empowering our community to share their experiences.
We will mobilise Voices for Change , �� progress.
We will harness the Power of Data to accelerate research, tackle inequality, empower choices, inform change and maximise our impact.

PLANS FOR THE FUTURE

Our goals remain unchanged, to defeat �� come, money that will be used to fund our �� best global research.

�� research grant commitments. The Trustees consider that there is a reasonable expectation that The Charity �� this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

In addition:’

We will continue identifying the best global research to be funded through a new round of research grant funding
We will complete and adopt our entirely new organisational strategy, Beyond Brain Tumours that we’re co-creating as a community.
�� the commercialisation of the intellectual property and technology underlying BRIAN (Brain tumouR Information and Analysis Network) - this does not include the data held in BRIAN.

Our new strategy that we are forming �� our direction and the charity we need to become in future years.

THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research and began funding new projects again, as well as raising awareness and supporting thousands of people ��

This work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

��

TRUSTS

CORPORATES

In addition to the donors named below, we would like to thank all our anonymous donors.

BBC Children in Need

Allports Group Atrato Capital Limited BECG Group Benesys Bluecube Technology Solutions

�� The AOK Trust

The Colin Oliphant Charitable Trust ��

�� Clicky Media CMC Markets

FAMILY-LED CHARITY PARTNERS

�� IHS Markit ��

��

�� Knight Security Group K&L Gates

�� Naseem’s Manx Brain Tumour Charity

��

Majestic Wine Microsoft Runningman Two Salesforce Thunderhead Underbelly

��

The Brian Cross Memorial Trust

�� Stay Strong Stu

The Brain Tumour Charity Annual Report and Accounts 2021-2022

CO-FUNDING PARTNERS

Action Medical Research Cancer Research UK Children with Cancer UK Great Ormond Street Hospital Children’s Charity

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Alastair Stewart OBE

��

Dominic Matteo Earl Spencer Ella and Matt Mills (Deliciously Ella) Guy Opperman MP Hal Cruttenden Holly Matthews Ian Chillcott

��

�� Lewis Moody OBE and Annie Moody Liam Conlon Lorraine Kelly OBE Marc Silk Matt Allwright Mel Giedroyc The Neales

Nick Baines (Peanut – Kaiser Chiefs) Nicki Chapman

��

Owain Arthur

�� Phil Spencer Russell Watson Sandy Lyle MBE Sherrie Hewson Sian Reese-Williams

��

Tchéky Karyo Tim Burgess and The Charlatans Tom Daley The Wanted

We’d also like to thank the actress and

�� Neil Dickson. Dawn has supported The ��

TRUSTEES AND GOVERNANCE

TRUSTEES

�� Dr. Elena Bechberger Dr. Rachel Edgar Simon Hay Sean Hird �� Philippa Murray Berendina Norton �� Professor Alan Palmer

Beth Worrall

��

The directors and trustees had liability ��

PRESIDENT

Professor Sir Colin Blakemore (passed away ��

CHIEF EXECUTIVE OFFICER

�� Graham Norton (Interim CEO appointed �� Graham Lindsay (Deputy-Interim CEO ��

COMPANY SECRETARY

��

CHARITY REGISTRATION NUMBERS

��

�� Michael Taylor �� Monika Hegi Neil Carragher Ola Rominiyi �� Pamela Kearns Paul Brennan Paul Northcott Paula Croal Petra Hamerlick Phedias Diamandis Philipp Euskirchen �� Rameen Beroukhim Richard Gilbertson �� Roger Packer Russ Hagen Sebastian Brandner Sébastien Serres Siddhartha Mitra Simon Bailey Simona Parrinello Sophie Thomas Spencer Watson �� Stuart Allan Stuart Smith Susan Short Terri Armstrong Thomas Würdinger Todd Hankinson Tyler Miller ��

COMPANY NUMBER

��

PRINCIPAL AND REGISTERED OFFICE

��

AUDITORS

��

BANKERS

��

INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street, ��

��

RESEARCHERS IN OUR COMMUNITY

�� ongoing contribution to our success.

Adam Waldman

Adel Samson Alex Bullock Andrew Peet Anthony Byrne Anthony Chalmers Antony Michalski Barry Pizer Catherine McBain �� Colin Kennedy Colin Watts Conor Mallucci ��

��

�� Denise Sheer Diane Puccetti Eric Aboagye

�� Gelareh Zadeh Gregor Hutter Ian Waddell

��

BIOMEDICAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Richard Gilbertson �� Dr Mark Gilbert �� Dr Susan Chang Dr Cynthia Hawkins Dr Paul Northcott Professor Simona Parrinello Professor Colin Watts Dr Duane Mitchell �� Dr Marcel Kool Dr Lucy Stead Dr Gerry Thompson

INSTITUTION

The Cambridge Cancer Centre, UK The Institute of Child Health, Newcastle �� National Institutes of Health (NIH), USA The Wellcome Trust Sanger Institute, UK �� The Hospital for Sick Children, Canada �� German Cancer Research Centre, Germany ��

��

PAEDIATRIC LOW GRADE CENTRE SAB

NAME

�� Dr Christian Dillon ��

INSTITUTION

�� Massachusetts General Hospital Erasmus MC Cancer Center, The Netherlands PhoreMost Ltd, Cambridge, UK Duke Cancer Institute, USA Translational Genomics Institute, Phoenix, USA

LAY ADVISORS

Ms Christina Brincat Mrs Deborah Crossan Mrs Rachel Rathbone Ms Louise Webber-Edwards ��

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered ��

�� of Trustees, the Board will take the �� group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees who are recruited are required to ��

�� listed on page 34.

The Trustees meet as a full Board four times per year and agree the broad strategy and �� grants, information and support strategy, �� and performance.

�� Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 8 to the accounts. Trustees are �� and, in accordance with The Charity’s policy, �� interest arises.

Day-to-day operations and management �� reports to the Trustees on performance and operations.

��

• Remuneration

• Technology Commercialisation

• Databank (BRIAN)

�� Board (Biomed SAB) and the Paediatric �� (Paediatric Low Grade Centre SAB) can be ��

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing �� all areas of the organisation and in The ��

The EDI committee comprising of at least �� two Trustees along with other members as required has the purpose of making �� and reporting on progress. This is aided by a �� forward all areas of EDI within The Charity.

GRANT-MAKING POLICY

The Charity has established its grant-making �� seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our new research strategy ‘ Accelerating a Cure �� by brain tumours. We fund research into �� open calls for applications for project grants, programme grants and clinical trials.

�� with a primary brain tumour each year and �� are the biggest cancer killer of children and ��

Research
Information and Support ��

�� programme are ultimately people with brain tumours and their families and carers.

The Brain Tumour Charity Annual Report and Accounts 2021-2022��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

We know that only research can make a �� outcomes for people with brain tumours.

�� research grants from institutions by �� through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our �� & Databank Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the �� assessment that is satisfactory.

APPROACH TO FUNDRAISING

�� Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code �� not engage with any third-party fundraisers during the year. We comply with the key �� training when they join The Charity.

�� to fundraising.

�� of practice during the year.

STATEMENT OF THE TRUSTEES’ RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing �� statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including ��

applicable in the UK and Republic of Ireland. Company law requires the Trustees to

�� the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for �� statements, the Trustees are required to:

Select suitable accounting policies and then apply them consistently.
�� Charities SORP.
Make judgements and estimates that are reasonable and prudent.
State whether applicable UK Accounting �� to any material departures disclosed and ��
�� the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are �� transactions and disclose with reasonable �� The Charity and the Group and enable them to �� responsible for safeguarding the assets of The Charity and the Group and hence for �� detection of fraud and other irregularities.

In so far as we are aware:

• �� which the charitable company's auditor is unaware.

�� and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic �� signed on their behalf by:

Jack Morris CBE

Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

�� Reporting Council's Ethical Standard, and we �� in accordance with these requirements. ��

OPINION

�� of The Brain Tumour Charity (the 'parent Reporting Council's Ethical Standard, and we charitable company') and its subsidiaries �� in accordance with these requirements. �� Consolidated balance sheet, the Company �� balance sheet, the Consolidated statement �� CONCLUSIONS RELATING �� TO GOING CONCERN �� been applied in their preparation is applicable �� law and United Kingdom Accounting �� the going concern basis of accounting in �� Standard applicable in the UK and Republic is appropriate. of Ireland' (United Kingdom Generally Accepted Accounting Practice).

�� the going concern basis of accounting in �� is appropriate.

�� the parent charitable company's ability to continue as a going concern for a period of at �� statements are authorised for issue.

��
�� the Group's and of the parent charitable �� of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;

Our responsibilities and the responsibilities of the Trustees with respect to going �� sections of this report.

�� with United Kingdom Generally Accepted Accounting Practice; and
��
��

OTHER INFORMATION

BASIS FOR OPINION

The other information comprises the information included in the Annual report �� our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our �� to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' �� statements section of our report. We are independent of the Group in accordance with

The Brain Tumour Charity Annual Report and Accounts 2021-2022

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially �� or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required �� there is a material misstatement of this other information, we are required to report that fact.

��

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

�� Report and Strategic Report for the �� statements are prepared are consistent ��
the Trustees' Report and Strategic Report �� applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company �� misstatements in the Trustees' Report or Strategic Report.

�� the following matters in relation to which �� you if, in our opinion:

the parent charitable company has not �� records, or returns adequate for our audit ��
�� statements are not in agreement with the accounting records and returns; or
certain disclosures of Trustees' remuneration ��

�� explanations we require for our audit: or

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the �� for such internal control as the Trustees determine is necessary to enable the �� free from material misstatement, whether due to fraud or error.

�� Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease �� but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

�� statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance �� guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error �� or in the aggregate, they could reasonably �� decisions of users taken on the basis of ��

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our �� material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

The charitable company is subject to laws �� reporting legislation. We determined that the following laws and regulations were �� and Health and Safety legislation, GDPR �� We assessed the extent of compliance with these laws and regulations as part �� statement items.

• We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries ��

The engagement partner assessed whether �� appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.

• We assessed the susceptibility of the �� to material misstatement, including how fraud might occur. We considered the �� exist within the organisation for fraud and �� the following areas:

Posting of fraudulent journal entries
Posting of fraudulent payments and receipts in the accounting software
Authorisation, processing, and payment of fraudulent expenses
��

��

Audit procedures performed by the engagement team included:
Identifying and assessing the design ��
Understanding how those charged with ��
Challenging assumptions and judgments �� accounting estimates; and

• Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations

Carrying out checks to establish the ��

�� which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading �� statements or non-compliance with regulation. This risk increases the more that compliance �� become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as �� collusion, omission or misrepresentation.

A further description of our responsibilities for �� www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance �� so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for ��

Janice Matthews

�� for and on behalf of

Menzies LLP

Chartered Accountants Statutory Auditor Centrum House

�� Egham Surrey

��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

CONSOLIDATED BALANCE SHEET AT 31 MARCH 2022

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2022

��

Unrestricted Funds Restricted Funds Notes £'000 £'000 `Income and expenditure` `Income from:` Donations and legacies 3 8,681 2,276 Other trading 161 32 Investments 325 - Total income 9,167 2,308 `Expenditure on:` Raising funds 1,872 1 Charitable activities Research 4,038 2,172 Patient support 1,394 386 Campaigning & raising awareness 760 2 Total expenditure on charitable activities 6,192 2,560 Total expenditure 4 8,064 2,561 Net income before gains and losses on investment assets 1,103 (253) Realised and unrealised gains on investment assets (97) - `Net income/(expenditure)` 1,006 (253) Transfers - - `Net movement in funds for the` `year` 1,006 (253) `Reconciliation of funds` Balances at 1 April 2021 3,348 3,509 Balances at 31 March 2022 4,354 3,256	Total 2022 Unrestricted Funds Restricted Funds £'000 £'000 £'000 10,957 6,577 1,180 193 171 15 325 355 - 11,475 7,103 1,195 1,873 1,742 2 6,210 5,405 1,239 1,780 1,724 371 762 829 20 8,752 7,958 1,630 10,625 9,700 1,632 850 (2,597) (437) (97) 2,656 - 753 59 (437) - (955) 955 753 (896) 518 6,857 4,244 2,991 7,610 3,348 3,509	Total 2021 £'000 7,757 186 355
		8,298 1,744 6,644 2,095 849
		9,588
		11,332
		(3,034) 2,656
		(378) - (378) 7,235
		6,857

Notes `Fixed assets` Intangible assets 10 Tangible assets 11 Investment in subsidiaries 12 Investments 12 `Current assets` Stock Debtors 13 Cash at bank `Creditors` Amounts falling due within one year 14 Provision for liabilities 15 `Net current (liabilities)/ assets` `Total assets less current liabilities` `Funds` General reserve Designated funds Unrestricted funds Restricted funds 19	Consolidated 2022 2021 £'000 £'000 15 34 267 281 - - 14,536 14,652 6 9 820 452 5,240 4,978 6,066 5,439 (13,174) (13,449) (100) (100) (7,208) (8,110) 7,610 6,857 2,662 1,752 1,692 1,596 4,354 3,348 3,256 3,509 7,610 6,857	Company 2022 2021 £'000 £'000 15 34 267 281 - - 14,536 14,652 - - 820 453 5,239 4,972 6,059 5,425 (13,208) (13,456) (100) (100) (7,249) (8,131) 7,569 6,836 2,621 1,731 1,692 1,596 4,313 3,327 3,256 3,509 7,569 6,836	Company 2022 2021 £'000 £'000 15 34 267 281 - - 14,536 14,652 - - 820 453 5,239 4,972 6,059 5,425 (13,208) (13,456) (100) (100) (7,249) (8,131) 7,569 6,836 2,621 1,731 1,692 1,596 4,313 3,327 3,256 3,509 7,569 6,836
			5,425 (13,456) (100)
			(8,131)
			6,836
			1,731 1,596
			3,327 3,509
			6,836

The financial statements were approved by the trustees on 15 September 2022 and signed on their behalf by:

………………………………….....	………………………………….....
Jack Morris CBE	Neil Dickson MBE Beth Worrall
Chair of Trustees	Vice-Chair of Trustees Chair of Finance Committee

The notes on pages 45-59 form part of these financial statements.

The Statement of Financial Activities includes all gains and losses recognised in the year. All incoming resources and resources expended derive from continuing activities.

The notes on pages 45-59 form part of these financial statements.

The Brain Tumour Charity Annual Report and Accounts 2021-2022

CONSOLIDATED CASH FLOW FOR THE YEAR ENDED 31 MARCH 2022

NOTES TO THE FINANCIAL STATEMENTS

`Reconciliation of net income to net cash flow from` `operating activities` `Net income for the year` `Adjustments for:` Depreciation Losses/ (gains) on investments Income from investments Provision for liabilities Loss/ (profit) on sale of fixed assets (Increase)/ decrease in stocks Decrease/ (increase) in debtors Increase / (decrease) in creditors `Net cash (used in)/ provided by operating activities` `Statement of cash flows` `Cash flows from operating activities` `Net cash (used in)/ provided by operating activities` `Cash flows from investing activities:` Dividends, interest and rents from investments Purchase of computer software Purchase of property plant & equipment Sale/(purchase) of investments `Net cash provided by/ (used in) investing activities` `Change in cash and cash equivalents in the year` Balances at 1 April 2021 Balances at 31 March 2022 `Analysis of cash and cash equivalents` Cash in hand Notice deposits (less than 3 months) `Total cash and cash equivalents` `Analysis of changes in net debt` At 1 April 2021 Cash from sale of investments Cash 2,944 19 Cash equivalents 2,034 - `Net debt` 4,978 19	2022 £'000 753 42 97 (325) - - 2 (367) (274) (72) 2022 £'000 (72) 325 - (10) 19 334 262 4,978 5,240 2022 £'000 5,240 - 5,240 Other Cash flows 2,277 (2,034)	2021 £'000 (378) 50 (2,619) (355) 100 2 2 268 541 (2,388) 2021 £'000 (2,388) 355 - (296) - 59 (2,328) 7,306 4,978 2021 £'000 2,944 2,034 4,978 At 31 March 2022 5,240 -




4,978 19	243	5,240

1. Statement of compliance

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 35. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 3.

2. Accounting policies

(a) `Basis of preparation of financial statements`

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity’s subsidiary undertaking, TBTC Trading Ltd has been consolidated on a line by line basis. TBTC Trading Ltd prepares its accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £733,000 (2021: outgoing £394,000).

The financial statements have been prepared under the historical cost convention.

`Judgements and key sources of estimation uncertainty`

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

`Significant judgements`

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

`Key sources of estimation uncertainty`

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

The Brain Tumour Charity Annual Report and Accounts 2021-2022

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) `Company status`

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 34. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

(c) `Income`

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) `Expenditure`

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Termination payments are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

Employee Termination Benefits are accounted for when notice is given to the employee concerned.

(e) `Stocks`

Stock is measured at the lower of cost and net realisable value.

(f) `Fund accounting`

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) `Fixed assets`

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) `Estimated useful lives`

The estimated useful lives of fixed assets are as follows:

Computer equipment 3 years Office equipment 5 years Leasehold improvements the lease term Computer software 5 years

(i) `Investments`

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) `Donated assets and services`

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) `Operating lease`

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) `Pensions`

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

The Brain Tumour Charity Annual Report and Accounts 2021-2022

(m) `Financial instruments`

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) `Going concern`

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The COVID-19 pandemic began to impact in March 2020 and continued to affect this financial year but with diminishing impact as the year went on and restrictions in the UK eased. The Charity’s income through fundraising from mass participation events or the holding of physical fundraising events started to return as the year went on. Similarly, daily activities of The Charity with employees working remotely shifted to a hybrid working model. Financial investments continued to be volatile as financial markets reacted to global events. The Charity demonstrated it can adapt to these changes and has returned to growth. This growth is expected to continue in the next twelve months and beyond.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. Donations and legacies

Unrestricted £'000 Ordinary activities: Regular giving 308 Donations, appeals and fundraising 6,756 Gift aid 815 Legacies 273 Government grants 529 8,681	Restricted £'000 39 1,949 45 243 - 2,276	2022 Total Unrestricted Restricted £'000 £'000 £'000 347 258 41 8,705 5,352 1,120 860 483 19 516 155 - 529 329 - 10,957 6,577 1,180	2021 Total £'000 299 6,472 502 155 329
			7,757

4. Analysis of resources expended

`Raising funds` `Charitable activities:` Research Patient support Campaigning and raising awareness `Total expenditure on charitable activities` `Total expenditure` `Raising funds` `Charitable activities:` Research Patient support Campaigning and raising awareness `Total expenditure on charitable activities` `Total expenditure` . Research grant cost analysis Research programmes Research projects Clinical trials Fellowships Conferences	Direct Costs £'000 1,721 1,085 1,706 675 3,466 5,187 Direct Costs £'000 1,579 1,167 2,019 769 3,955 5,534		Grants £'000 - 5,079 - - 5,079 5,079 Grants £'000 - 5,446 - - 5,446 5,446 2022 £'000 3,640 1,145 299 - (5)	Support Costs 2022 Total £'000 £'000 152 1,873 46 6,210 74 1,780 87 762 207 8,752 359 10,625 Support Costs 2021 Total £'000 £'000 165 1,744 31 6,644 76 2,095 80 849 187 9,588 352 11,332 2021 £'000 4,406 831 155 54 - 5,446	2022 Total £'000 1,873 6,210 1,780 762
					8,752
					10,625
					2021 Total £'000 1,744 6,644 2,095 849
					9,588
					11,332

			5,079

5. Research grant cost analysis

A breakdown of research costs by individual award is provided in note 22.

Government grants consist of amounts received under the Government Coronavirus Job Retention Scheme and the COVID Medical Research Charity Support Fund.

The Brain Tumour Charity Annual Report and Accounts 2021-2022

6. Support costs by activity

Finance and human resources £'000 `Raising funds` 44 `Charitable activities:` Research 13 Patient support 21 Campaigning and raising awareness 25 `2022 Total` 103 Finance and human resources £'000 `Raising funds` 54 `Charitable activities:` Research 10 Patient support 25 Campaigning and raising awareness 26 `2021 Total` 115	Central facilities Information technology Central management Governance £'000 £'000 £'000 £'000 25 44 11 28 7 14 4 8 12 22 6 13 14 25 7 16 58 105 28 65 Central facilities Information technology Central management Governance £'000 £'000 £'000 £'000 19 37 17 38 4 7 3 7 9 17 8 17 9 19 8 18 41 80 36 80	Total £'000 152 46 74 87
		359
		Total £'000 165 31 76 80
		352

During the year redundancy payments were made totalling £nil (2021: £29,000). At 31 March 2022 there was £nil provided (2021 £nil).

The average number of employees during the year was 86 (2021: 108).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2022	2021
£60,001 - £70,000	2	1
£70,001 - £80,000	1	1
£80,001 - £90,000	1	1
£90,001-£100,000	-	-

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £453,000 (2021: £572,000).

9. Taxation

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

10. Intangible fixed assets

`Group and Company`

7. Governance costs

Auditor's remuneration Legal and professional fees Staff	2022 £'000 15 - 50 65	2021 £'000 20 3 57
		80

In addition to Auditor’s remuneration for audit shown above, a further £4,500 was paid for accounting and tax advice. Trustees received no remuneration (2021: £nil). Trustees received no reimbursement for travel expenses in the year totalling £nil (2021: one for £26). The premium in respect of professional liability insurance covering trustee indemnity was £nil (2021: £nil).

	Computer Software
	£'000
`Cost`
At 1 April 2021	161
Additions	-
At 31 March 2022	161
`Depreciation`
At 1 April 2021	128
Charge for the year	18
At 31 March 2022	146
`Net book value`
At 31 March 2022	15
At 31 March 2021	34

8. Staff costs

Wages and salaries Social security costs Payments to defined contribution pension plans	Group 2022 2021 £'000 £'000 2,776 3,402 223 311 223 296 3,222 4,009	Company 2022 2021 £'000 £'000 2,776 3,402 223 311 223 296 3,222 4,009	Company 2022 2021 £'000 £'000 2,776 3,402 223 311 223 296 3,222 4,009
			4,009

The Brain Tumour Charity Annual Report and Accounts 2021-2022

Cost of sales represent cost of stock sold in the year.

11. Tangible fixed assets

`Group and Company`

Leasehold Improvements £'000 `Cost` At 1 April 2021 289 Additions 3 At 31 March 2022 292 `Depreciation` At 1 April 2021 14 Charge for the year 19 At 31 March 2022 34 `Net book value` At 31 March 2022 258 At 31 March 2021 274	Computers and Office Equipment £'000 168 6 174 161 4 165 9 7	Total £'000 457 9
		466
		175 24
		199

		267
		281

12. Investments

`(a) Subsidiary Investment`

`Subsidiary Investment`
Equity investment in group undertakings `Cost` At 1 April 2021 Additions At 31 March 2022	£ 100 100
	200

On 3 March 2022 The Charity formed a new subsidiary Acquist Data Holding Limited. The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holding Limited, a dormant company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Limited owns 100% of Acquist Data Limited, a dormant company incorporated in England and Wales, company number 13951572

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

At 31 March 2022 the aggregate of the share capital and reserves of TBTC Trading Ltd was £21,000 (2021: £21,000).

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

Turnover Cost of sales Gross profit Other operating expenses Profit before donation Donation Retained profit/ (loss)	2022 £'000 59 (15) 44 (3) 41 (21) 20	2021 £'000 49 (12)
		37 (16)
		21 (4)
		17

At 31 March 2022 the aggregate assets of TBTC Trading Ltd were £45,000 (2021: £24,000), aggregate liabilities £4,000 (2021: £3,000) and shareholder’s funds £41,000 (2021: £21,000).

`(b) General investments`

`Group and Company` At 1 April Additions at cost Disposals Net unrealised (loss) on revaluation At 31 March Historical cost Investments at market value comprised: UK equities Overseas equities Absolute return funds Property Multi asset funds Alternative investments Fixed income securities Cash held within the investment portfolios Accrued income At 31 March	2022 £'000 14,652 635 (533) (218) 14,536 12,306 2022 £'000 3,236 3,679 418 124 509 287 3,421 2,862 - 14,536	2021 £'000 12,033 1,464 (4,541) 5,696
		14,652
		12,204
		2021 £'000 3,775 3,539 442 - 234 578 3,184 2,900 -
		14,652

During the year income from listed investments was £324,000 (2021: £350,000) and interest on deposits £1,000 (2021: £4,000).

13. Debtors

Trade debtors Accrued income and prepayments Other debtors Amounts owed by TBTC Trading Ltd	Consolidated 2022 2021 £'000 £'000 373 74 446 353 1 26 - - 820 453	Company 2022 2021 £'000 £'000 373 74 446 353 1 26 - - 820 453	Company 2022 2021 £'000 £'000 373 74 446 353 1 26 - - 820 453
			453

The Brain Tumour Charity Annual Report and Accounts 2021-2022

14. Creditors

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2022 £191,000 (2021: £297,000) of income was deferred and £357,000 (2021: £97,000), brought forward from previous periods, was released.

Grants payable Accruals and deferred income Trade creditors Other creditors Social security and other taxes Amounts owed to TBTC Trading Ltd	Consolidated 2022 2021 £'000 £'000 12,650 12,293 381 468 38 593 28 28 77 67 - - 13,174 13,449	Company 2022 2021 £'000 £'000 12,650 12,294 378 465 38 593 28 28 76 67 38 9 13,208 13,456	Company 2022 2021 £'000 £'000 12,650 12,294 378 465 38 593 28 28 76 67 38 9 13,208 13,456
			13,456

15. Provision for liabilities

At 1 April 2021 Additions Disposals At 31 March 2022	Consolidated 2022 2021 £'000 £'000 100 - - 100 - - 100 100	Company 2022 2021 £'000 £'000 100 - - 100 - - 100 100	Company 2022 2021 £'000 £'000 100 - - 100 - - 100 100
			100

The provision related to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. Research commitments

17. Operating lease commitments

The total of future minimum property lease payments on operating leases are as follows:

Within one year Between one and five years	Consolidated 2022 2021 £'000 £'000 301 143 1,182 1,242 1,483 1,385	Company 2022 2021 £'000 £'000 301 143 1,182 1,242 1,483 1,385	Company 2022 2021 £'000 £'000 301 143 1,182 1,242 1,483 1,385
			1,385

Operating lease charges during 2022 were £57,000 for property (2021: £30,000).

18. Analysis of net assets between funds

Intangible fixed assets Tangible fixed assets Investments Other current assets Current liabilities Intangible fixed assets Tangible fixed assets Investments Other current assets Current liabilities	Unrestricted Funds £'000 15 267 14,536 (887) (9,577) 4,354 Unrestricted Funds £'000 34 281 14,652 (1,572) (10,047) 3,348	Restricted Funds £'000 - - - 6,953 (3,697) 3,256 Restricted Funds £'000 - - - 7,011 (3,502) 3,509	Total 2022 £'000 15 267 14,536 6,066 (13,274)
			7,610
			Total 2021 £'000 34 281 14,652 5,439 (13,549)
			6,857

At 31 March 2021 The Charity had authorised commitments that were subject to outstanding conditions amounting to £8,254,000 (2021: £13,586,000), these are expected to fall due as follows:

follows:
Within one year Between one and two years Between two and three years Between three and four years Between four and five years Five years and further	2022 £'000 3,712 2,768 1,361 134 134 145 8,254	2021 £'000 5,736 3,609 2,546 1,283 133 279
		13,586

The above commitments will be funded from reserves and future income.

( ) ( )

The Brain Tumour Charity Annual Report and Accounts 2021-2022

19. Funds

`Consolidated` At 1 April 2021 £'000 `Restricted funds:` Research funds 2,056 Everest fund 486 Awareness funds 383 Support funds 584 3,509 `Unrestricted funds:` General reserve 1,752 Designated funds 1,596 3,348 6,857 `Company` At 1 April 2021 £'000 `Restricted funds:` Research funds 2,056 Everest fund 486 Awareness funds 383 Support funds 584 3,509 `Unrestricted funds:` General reserve 1,731 Designated funds 1,596 3,327 6,836	Incoming resources £'000 1,637 191 2 478 2,309 8,112 1,054 9,166 11,475 Incoming resources £'000 1,637 191 2 478 2,30� 8,053 1,054 9,107 11,416	Resources expended £'000 (1,495) (677) (3) (387) (2,562) (7,105) (958) (8,063) (10,625) Resources expended £'000 (1,495) (677) (3) (387) (2,56�� (7,087) (958) (8,046) (10,607)	Fund transfers Investment gains At 31 March 2022 £'000 £'000 £'000 - - 2,198 - - - - - 382 - - 675 - - 3,256 - (97) 2,662 - - 1,692 - (97) 4,354 - (97) 7,610 Fund transfers Investment gains At 31 March 2022 £'000 £'000 £'000 - - 2,198 - - - - - 382 - - 675 - - 3,256 21 (97) 2,621 - - 1,692 21 (97) 4,313 21 (97) 7,569	Fund transfers Investment gains At 31 March 2022 £'000 £'000 £'000 - - 2,198 - - - - - 382 - - 675 - - 3,256 - (97) 2,662 - - 1,692 - (97) 4,354 - (97) 7,610 Fund transfers Investment gains At 31 March 2022 £'000 £'000 £'000 - - 2,198 - - - - - 382 - - 675 - - 3,256 21 (97) 2,621 - - 1,692 21 (97) 4,313 21 (97) 7,569
				3,256
				2,621 1,692
				4,313
				7,569

`Consolidated`	At 1 April	Incoming	Resources	Fund	Investment	At 31 March
	2020	resources	expended	transfers	gains	2021
	£'000	£'000	£'000	£'000	£'000	£'000
`Restricted funds:` Research funds Everest fund	684 1,395	635 36	(294) (945)	1,031 -	- -	2,056 486
Awareness funds	392	6	(15)	-	-	383
Support funds	520 2,991	518 1,194	(378) (1,631)	(77) 955	- -	584 3,509
`Unrestricted funds:`
General reserve	2,499	6,244	(8,693)	(955)	2,656	1,752
Designated funds	1,744 4,243 7,235	859 7,103 8,297	(1,007) (9,700) (11,332)	- (955) -	- 2,656 2,656	1,596 3,348 6,857
`Company`	At 1 April	Incoming	Resources	Fund	Investment	At 31 March
	2020	resources	expended	transfers	gains	2021
	£'000	£'000	£'000	£'000	£'000	£'000
`Restricted funds:`
Research funds Everest fund Awareness funds Support funds `Unrestricted funds:` General reserve Designated funds	684 1,395 392 520 2,991 2,495 1,744 4,239 7,230	635 36 6 518 1,194 6,195 859 7,054 8,248	(294) (945) (15) (378) (1,631) (8,665) (1,007) (9,672) (11,303)	1,031 - - (77) 955 (950) - (950) 4	- - - - - 2,656 - 2,656 2,656	2,056 486 383 584 3,509 1,731 1,596 3,327 6,836

PURPOSE OF RESTRICTED FUNDS

Research funds Everest fund Awareness funds Support funds

Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 22. During 2015/16 we received exceptional income of £2,889,949 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours. Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is HeadSmart: be brain tumour aware. Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

The Brain Tumour Charity Annual Report and Accounts 2021-2022

Designated funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

20. Related parties

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2022 The Charity owed TBTC Trading Ltd £37,933 (2021: £9,444).

The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited. Acquist Data Holdings Limited and Acquist Data Limited were dormant in the financial year. At 31 March 2022 The Charity owed Acquist Data Holdings Limted £100 (2021: £nil).

Trustees, their close family members and entities they control, made donations to The Charity totalling £41,336 during the year (2021: £16,783) and paid contributions totalling £381 (2021: £nil) during a number of our fundraising events.

21. Grants receivable

During the year The Charity received support from the following trusts and foundations, where donations were restricted or designated to specific areas of activity as follows:

Trust and foundation £'000 Albert Gubay Charitable Foundation 141

Charitable activity Restrict fund for Research

22. Research awards

Project - Expanding Theories 2019/2 - French - Erasmus Project - Expanding Theories 2019/2 - Brandner - UCL Project - Future Leaders 2019 - Croal - Nottingham Project - Future Leaders 2019 - Watson - Lausanne Project - Future Leaders 2019 - Miller - Massachusetts Project - Future Leaders 2019 - Rendo - Dana-Farber Project - Quality of Life 2019 - Byrne - Cardiff Conferences and workshops - Kennedy - Southampton Other Programme - Chesler - ICR - Medullo super enhancers Programme - Pollard - University Edinburgh - Chromatin targets in GBM Programme - Jones - DKFZ - Everest Centre Programme - Kennedy - University Southampton - PNET5 QoL Programme - Wurdinger - VU Amsterdam - WINDOW Programme - Zadeh - University Health Network - Clinically aggressive meningiomas Programme - Northcott - St Judes - MERIT Programme - Hankinson - University Colorado - Adamantinomous craniopharyngioma Programme - Parrinello - UCL - Mapping spatio-temporal heterogenity Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC Programme - Carragher - University Edinburgh - Therapeutic combinations in GBM Project - Edinburgh - Brenan Project - Development of a novel tumour-targeting thermogel activated by Matrix Metalloproteinases Project – Clark – UCL Neurocognitive effects of medullo Project - Kennedy - University Southampton - PROMOTE Project - Rooney - University Edinburgh - BT LIFE Project - Sharp - Newcastle University - Self-supporting management for survivors Project - Northcott - St Judes - Refining medullo in USA clinical trials Project - van den Bent - Erasmus Medical Centre - Refining glioma classification in CATNON trial Project - Taphoorn - Leiden University Medical Centre - Defining patient reported outcomes Project - Hawkins - Uni Birmingham - Combining child and young adult data for better monitoring Project - Thomas - Nottingham Childrens' Hospital - AC therapy in young people Project - Schuemann - Massachusetts General Hospital - Extreme dose rate proton therapy Project - Hegi - Lausanne - MGMT methylation Project - Smith - Nottingham - RNA methylation Project - Rominiyi - Sheffield - Ex-vivo 3D models Clinical Trial - Kearns - University Birmingham - PNET5 CTU Clinical Trial - HR-MB - Bailey - Newcastle Clinical Trial - ARISTOCRAT - Short - Leeds Fellowship - Bihannic - St Jude - Origins of Groups 3 and 4 medullo Programme - Quest for Cures 2019 - Chesler ICR Programme - Quest for Cures 2019 - Beroukhim - Dana-Farber Project - Clinical Biomarkers 2019/2 - Zadeh - UHN Project - Clinical Biomarkers 2019/2 - Euskirchen - Charite Hospital	60 60 58 56 66 36 60 60 60 60 60 60 65 88 (5) - - (85) 5,079 5,446 2022 2021 £'000 £'000 308 306 - 317 914 945 45 43 - 387 130 300 130 291 267 216 357 339 299 238 564 578 - (73) - (7) - (73) - (22) - (28) 111 - 100 100 - 18 - 43 18 140 82 - - 56 42 - - 60 60 - 44 44 109 111 146 - - 54 296 338 329 195 207 96 96 101	60 60 58 56 66 36 60 60 60 60 60 60 65 88 (5) - - (85) 5,079 5,446 2022 2021 £'000 £'000 308 306 - 317 914 945 45 43 - 387 130 300 130 291 267 216 357 339 299 238 564 578 - (73) - (7) - (73) - (22) - (28) 111 - 100 100 - 18 - 43 18 140 82 - - 56 42 - - 60 60 - 44 44 109 111 146 - - 54 296 338 329 195 207 96 96 101
		5,446

The Brain Tumour Charity Annual Report and Accounts 2021-2022

��

�� Registered Charity in England and ��

The Brain Tumour Charity Annual Report and Accounts 2021-2022

CONTENTS

CHAIR’S REPORT

First of all, may I start with a heartfelt thank you for standing ������������������������������

Jack Morris CBE

YOUNG AMBASSADORS

Amy

Kajal

Jazz

Rhudi

Rebecca

Kate

CEO’S REPORT

�������������������������

Graham Norton

OUR GOALS AND VALUES

OUR GOALS

OUR VALUES

PIONEERING

PASSIONATE

COLLABORATIVE

SMART

CLARE NORMAND, OUR HEAD OF STRATEGY, HONOURED WITH OBE

David Jenkinson

OUR OBJECTIVES AND ACTIVITIES

DEFEATING BRAIN TUMOURS: LEANING IN

PUBLIC BENEFIT STATEMENT

Power of Data

Best Care Everywhere

Voices for Change

Make it Count

THE GIFT OF TIME

Watch the

Tom Buckley

����������������

HIGHLIGHTS TAKING BRIAN TO OF 2021/22 THE NEXT LEVEL

IMPROVING SAFE AND SECURE ACCESS TO DATA

FUNDING NEW LAUNCHING OUR RESEARCH NEW RESEARCH STRATEGY

The Involvement Network

CELEBRATING OUR FOUNDERS

Dr David Jenkinson

HIGHLIGHTS CONTINUING TO MEET THE OF 2021/22 GROWING DEMAND FOR OUR SUPPORT SERVICES

AMPLIFYING THE COMMUNITY’S VOICE TO MAKE MEANINGFUL CHANGES IN CARE

SUPPORTING HEALTHCARE PROFESSIONALS

AN AWARD-WINNING PARTNERSHIP

Gina Almond

HIGHLIGHTS ACHIEVING RECORDOF 2021/22 BREAKING INCOME

LIVING UP TO OUR VALUES AS PIONEERS

FORGING AN AWARDWINNING PARTNERSHIP

Throughout 2021/22 we also developed two new campaigns that will launch in the summer of 2022, our Win Big Weekly Lottery and our long-awaited signs and symptoms campaign – Better Safe Than Tumour.

CELEBRATING OUR CELEBRITY SUPPORTERS

REACHING AND MOBILISING MORE VOICES FOR CHANGE

MAKING SURE THE COMMUNITY’S VOICE IS PRESENT IN EVERYTHING WE DO

Neil Munn

BRINGING OUR TEAM BACK TOGETHER

HIGHLIGHTS ADAPTING TO A NEW NORMAL OF 2021/22

COMMERCIALISING BRIAN

CELEBRATING OUR VOLUNTEERS

EMBRACING A NEW WAY OF FUNDING RESEARCH

LEANING IN TO OUR RESPONSIBILITY FOR EQUALITY, DIVERSITY AND INCLUSION

EXCEPTIONAL RE-APPOINTMENT OF TRUSTEES

FINANCE REVIEW

INCOME

EXPENDITURE

INVESTMENTS AND CASH

RESERVES POLICY

INVESTMENT POLICY

EMPLOYEES

RISK FACTORS

��� ��������������������������������

GOING CONCERN

OBJECTIVES FOR 2022-23

PLANS FOR THE FUTURE

In addition:’

THANKS

TRUSTS

CORPORATES

FAMILY-LED CHARITY PARTNERS

CO-FUNDING PARTNERS

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

First of all, may I start with a heartfelt thank you for standing ��

��

��

��

��

(a) `Basis of preparation of financial statements`

`Judgements and key sources of estimation uncertainty`

`Significant judgements`

`Key sources of estimation uncertainty`

(b) `Company status`

(c) `Income`

(d) `Expenditure`

(e) `Stocks`

(f) `Fund accounting`

(g) `Fixed assets`

(h) `Estimated useful lives`

(i) `Investments`

(j) `Donated assets and services`

(k) `Operating lease`

(l) `Pensions`

(m) `Financial instruments`

(n) `Going concern`

`Group and Company`